Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 18.27 USD -1.24% Market Closed
Market Cap: $2.8B

Net Margin

-31.6%
Current
Improving
by 65.9%
vs 3-y average of -97.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-31.6%
=
Net Income
$-79.9m
/
Revenue
$252.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-31.6%
=
Net Income
$-79.9m
/
Revenue
$252.8m

Peer Comparison

Country Company Market Cap Net
Margin
US
Adaptive Biotechnologies Corp
NASDAQ:ADPT
2.8B USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.2T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
223.2B USD
Loading...
US
Danaher Corp
NYSE:DHR
154.9B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
81.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.3B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
275.2B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
37.4B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.2B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.6B EUR
Loading...

Market Distribution

Lower than 78% of companies in the United States of America
Percentile
22nd
Based on 15 072 companies
22nd percentile
-31.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Adaptive Biotechnologies Corp
Glance View

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
6.42 USD
Overvaluation 65%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-31.6%
=
Net Income
$-79.9m
/
Revenue
$252.8m
What is Adaptive Biotechnologies Corp's current Net Margin?

The current Net Margin for Adaptive Biotechnologies Corp is -31.6%, which is above its 3-year median of -97.5%.

How has Net Margin changed over time?

Over the last 3 years, Adaptive Biotechnologies Corp’s Net Margin has increased from -131.8% to -31.6%. During this period, it reached a low of -132.3% on Dec 31, 2023 and a high of -31.6% on Sep 30, 2025.

Back to Top